Overview
The legal landscape for research peptides in the UK can be confusing. This guide explains the current regulatory framework in plain English, covering what is legal to buy and possess for research purposes, which peptides are classified as prescription-only medicines, and the recent MHRA alerts about counterfeit weight-loss injections.
This guide is for educational purposes only and does not constitute legal advice.
Research Peptides vs Licensed Medicines
In the UK, peptides fall into different regulatory categories depending on their status:
Research Peptides (Legal for Research Use)
Most peptides sold by research supply companies are legal to purchase and possess in the UK for research purposes only. These are typically sold as lyophilised powders labelled "not for human consumption" or "for research use only," and are not licensed as medicines by the MHRA (Medicines and Healthcare products Regulatory Agency).
Key points:
- It is legal to buy, possess, and store research peptides for legitimate research purposes
- They must not be marketed, sold, or supplied for human consumption
- Suppliers typically label products clearly as "research use only"
- The MHRA does not regulate research peptides as medicines because they are not licensed for therapeutic use
Prescription-Only Medicines (POM)
Some peptides that have been licensed as medicines in the UK are classified as Prescription-Only Medicines (POM). This means:
- They can only be legally supplied via a valid prescription from a qualified healthcare professional
- Supplying them without a prescription is illegal
- Possessing them without a prescription is not itself a criminal offence, but supply without a prescription is
Examples of POM peptides include:
- Semaglutide (Ozempic, Wegovy) — licensed for type 2 diabetes and obesity
- Liraglutide (Victoza, Saxenda) — licensed for type 2 diabetes and weight management
- Tirzepatide (Mounjaro) — licensed for type 2 diabetes and obesity
- Tesamorelin (Egrifta) — licensed for HIV-associated lipodystrophy (US-approved; not UK-licensed)
Unlicensed Investigational Peptides
Many peptides currently in clinical trials (e.g., retatrutide, survodutide, cagrilintide, orforglipron) are not licensed as medicines anywhere in the world. They are legal to purchase and possess as research chemicals, but they are not approved for human therapeutic use. Researchers should be aware that:
- These compounds have not completed the MHRA's safety, quality, and efficacy assessment
- Long-term safety data may be limited
- Their legal status could change if they receive marketing authorisation in the future
MHRA Regulation Explained
The MHRA is the UK government agency responsible for regulating medicines, medical devices, and blood components. Its key functions relevant to peptides include:
- Licensing medicines: The MHRA grants marketing authorisations (product licences) after reviewing safety, quality, and efficacy data. Only licensed medicines can be legally marketed for therapeutic use.
- Controlling supply: The MHRA enforces rules on who can supply medicines. Prescription-only medicines can only be supplied through pharmacies with a valid prescription.
- Monitoring safety: The MHRA monitors adverse drug reactions through the Yellow Card scheme and issues safety alerts when needed.
- Tackling falsified medicines: The MHRA works to identify and remove counterfeit and falsified medicines from the UK supply chain.
Research peptides that are not licensed medicines fall outside the MHRA's medicines regulation framework, provided they are genuinely sold and used for research purposes only.
⚠️ MHRA Warning: Counterfeit GLP-1 Weight-Loss Injections (June 2024)
In June 2024, the MHRA issued a safety alert warning the UK public about counterfeit semaglutide injection pens entering the UK supply chain. This is a significant regulatory development that all peptide researchers should be aware of.
Key details of the MHRA alert
- Counterfeit semaglutide pens (mimicking Ozempic and Wegovy packaging) were being sold via unregulated online pharmacies and social media platforms
- Some counterfeit products contained no active ingredient, while others contained incorrect or dangerous substances
- Risks included incorrect dosing, contamination, and absence of active ingredient
- The MHRA advised the public to only obtain GLP-1 weight-loss medicines via legitimate NHS or regulated private prescriptions
What this means for peptide researchers
- Source all GLP-1 agonist peptides (semaglutide, liraglutide, tirzepatide, etc.) from reputable, verified suppliers only
- Be cautious of any supplier offering "branded" injection pens at unusually low prices
- Verify that research-grade peptides come with proper documentation (COAs, purity testing)
- The MHRA's enforcement activity may increase scrutiny on all peptide suppliers in the UK
Source: MHRA. "MHRA warns public about fake semaglutide weight-loss injections." GOV.UK, June 2024. Available at: https://www.gov.uk/government/news/mhra-warns-public-about-fake-semaglutide-weight-loss-injections.
Controlled Substances
A small number of peptides and related compounds are classified as controlled substances under the Misuse of Drugs Act. For example, growth hormone releasing peptides that are chemically related to controlled substances may fall under tighter restrictions. Most research peptides, however, are not controlled substances.
If in doubt about the legal status of a specific compound, consult the MHRA's guidance or seek professional legal advice.
Practical Guidance for UK Researchers
- Buy from reputable suppliers: Choose vendors that provide Certificates of Analysis (COAs), third-party purity testing, and transparent business practices. See our Vendor Vetting Guide.
- Keep research use documentation: If purchasing peptides for research, maintain records of your research purpose, supplier invoices, and handling protocols.
- Do not supply to others for human use: Supplying unlicensed peptides for human consumption could constitute an offence under UK medicines law.
- Stay informed about regulatory changes: The MHRA regularly updates its guidance. Check the GOV.UK MHRA page for the latest alerts.
- Be aware of the counterfeit risk: The June 2024 MHRA alert highlights that the growing demand for GLP-1 weight-loss drugs has created a market for counterfeit products. Exercise extra caution with any GLP-1 agonist sourced outside regulated channels.
Summary Table
| Category | Legal to buy/possess for research? | Legal for human therapeutic use? | Examples |
|---|---|---|---|
| Research peptides (unlicensed) | Yes | No | BPC-157, TB-500, GHK-Cu, MOTS-c, CJC-1295 |
| Investigational peptides (in trials) | Yes | No | Retatrutide, survodutide, cagrilintide, orforglipron |
| POM peptides (UK-licensed) | No (without prescription) | Yes (with prescription) | Semaglutide, liraglutide, tirzepatide |
| Controlled substances | Restricted | No (without authorisation) | Varies — check Misuse of Drugs Act |
References
- MHRA. "MHRA warns public about fake semaglutide weight-loss injections." GOV.UK, June 2024. Available at: https://www.gov.uk/government/news/mhra-warns-public-about-fake-semaglutide-weight-loss-injections.
- Medicines and Healthcare products Regulatory Agency (MHRA). Guidance on medicines regulation. Available at: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.
- Human Medicines Regulations 2012. Available at: https://www.legislation.gov.uk/uksi/2012/1916/contents.
- Misuse of Drugs Act 1971. Available at: https://www.legislation.gov.uk/ukpga/1971/38/contents.